These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1406880)

  • 1. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis.
    Brandjes DP; Heijboer H; Büller HR; de Rijk M; Jagt H; ten Cate JW
    N Engl J Med; 1992 Nov; 327(21):1485-9. PubMed ID: 1406880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
    Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
    N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Pineo GF; Green D; Trowbridge AA; Elliott CG; Lerner RG; Hall J; Sparling T; Brettell HR
    N Engl J Med; 1992 Apr; 326(15):975-82. PubMed ID: 1545850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
    Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
    Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Panju AA; Brill-Edwards P; Ginsberg JS; Hirsh J; Martin GJ; Green D
    N Engl J Med; 1990 May; 322(18):1260-4. PubMed ID: 2183055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery.
    Agnelli G; Piovella F; Buoncristiani P; Severi P; Pini M; D'Angelo A; Beltrametti C; Damiani M; Andrioli GC; Pugliese R; Iorio A; Brambilla G
    N Engl J Med; 1998 Jul; 339(2):80-5. PubMed ID: 9654538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
    N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
    Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
    Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
    N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation.
    Hull R; Raskob G; Pineo G; Rosenbloom D; Evans W; Mallory T; Anquist K; Smith F; Hughes G; Green D
    N Engl J Med; 1993 Nov; 329(19):1370-6. PubMed ID: 8413432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.
    Nurmohamed MT; van Riel AM; Henkens CM; Koopman MM; Que GT; d'Azemar P; Büller HR; ten Cate JW; Hoek JA; van der Meer J; van der Heul C; Turpie AG; Haley S; Sicurella A; Gent M
    Thromb Haemost; 1996 Feb; 75(2):233-8. PubMed ID: 8815566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
    Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
    N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.
    Levine MN; Hirsh J; Gent M; Turpie AG; Weitz J; Ginsberg J; Geerts W; LeClerc J; Neemeh J; Powers P
    Thromb Haemost; 1995 Aug; 74(2):606-11. PubMed ID: 8584992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low-molecular-weight heparin without oral anticoagulants for the treatment of deep vein thrombosis].
    Alonso Martínez JL; Abínzano Guillén ML; Urbieta Echezarreta MA; Annichérico Sánchez FJ; Fernández Ladrón V; García Sanchotena JL
    An Med Interna; 2008 Jan; 25(1):4-8. PubMed ID: 18377187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.